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Circulating levels of IGF-I and IGFBP-3 in gastric cancer
Konca ALTINKAYNAK1, Mehmet BİLİCİ2, Nuri BAKAN3, Fatih AKÇAY3

Aim: To explore the causative mechanism of gastric carcinoma and to investigate the roles of circulating IGF-I and
IGFBP-3 in gastric cancer.
Materials and methods: Serum IGF-I and IGFBP-3 concentrations were measured using a 2-site coated tube
immunoradiometric assay.
Results: Serum IGF-I and IGFBP-3 values in gastric cancer patients were significantly lower compared to those in the
control group. The difference between serum IGF-I/IGFBP-3 in patients and the control group was not significant.
Conclusion: The low serum IGF-I and IGFBP-3 levels detected in patients with gastric cancer could be due to decreased
synthesis or increased catabolism of IGF-I or both. It could be suggested that these parameters may be important in the
development and prognosis of gastric cancer.
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Introduction
The insulin-like growth factor (IGF) family of peptide
ligands (IGF-I and IGF-II), the IGF-I and IGF-II
receptors, the 6 IGF-binding proteins (IGFBPs), and
the IGFBP proteases are fundamentally involved in
the regulation of somatic growth, cell proliferation,
transformation, and apoptosis. The biological
activities of the IGFs are modulated by IGFBPs,
which have higher affinity for IGFs than for the IGF
receptors (1–3). The IGF system is widely involved in
human carcinogenesis (4,5). Numerous studies have
demonstrated that IGFs and IGFBPs are produced by
tumor cell lines and tumors, acting as an autocrine
growth factor (6,7), and circulating concentrations
of IGF-I may be associated with an increased risk of
cancer (8,9), whereas IGFBP-3 concentrations may
be associated with a decreased cancer risk (10,11).
A number of prospective studies have identified
high plasma levels of IGF-I as a potential risk factor

for several malignancies, and showed associations
between IGF-I and prostate cancer, premenopausal
breast cancer, and colon cancer (12–14).
Normal growth and the differentiation of cells in
the gastrointestinal tract are regulated by autocrine
and paracrine secretion of peptide growth factors,
which are responsible for controlling maturation,
differentiation, and apoptosis (15). Gastric cancer is
one of the most common neoplasms and a leading
cause of death worldwide (15). According to data
from the Turkish Ministry of Health, gastric cancer
occupies first place among cancer incidence in males
and second place in females around Erzurum and
Van (16). There is evidence that the upregulation of
certain growth factors could play an important role
in the promotion and development of gastric cancer.
IGFs and their receptors may be important in the
regulation of epithelial cell growth, but few data are
available on the expression and biological function of
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the IGF system in gastric cancer. Durrant et al. (17)
have reported that IGF-I could facilitate the growth
of 3 cell strains of gastric carcinoma in vitro.
The aim of the present work was to investigate
the roles of circulating IGF-I and IGFBP-3 in gastric
cancer.

Statistics
All data were entered into an SPSS database (SPSS,
version 10.0, Chicago, IL, USA). IGF-I and IGFBP-3
values were expressed as mean ± SD. The significance
of differences between groups was assessed using
Student’s t test. A P value < 0.05 was considered
significant.

Materials and methods
Patients

Results

Thirty patients (16 males; with mean age ± SD of 57.3
± 14.3 years) and 35 clinically healthy subjects (17
males; with mean age ± SD of 56.8 ± 9.7 years) were
included in the study. Informed consent was obtained
from all patients. None of the patients were receiving
chemotherapy and all were newly diagnosed. Tumors
were classified according to UICC criteria (18).
Thirty had adenocarcinoma. All patients were in
stage IV and had distant organ–tissue metastases.
Tables 1 and 2 show the localization and metastatic
sites of patients with gastric cancer.

Table 3 shows levels of IGF-I and IGFBP-3 in the
serum of patients with gastric cancer and of the
controls. In this study, serum IGF-I and IGFBP-3
values in gastric cancer patients were significantly
lower compared to those in the control group but the
difference in the serum IGF-I/IGFBP-3 ratio between
patients and controls was not significant.

Biochemical assay
Blood samples were drawn into nonadditive vacutainer
tubes and centrifuged at 3000 × g at 4 °C for 10 min,
and sera were stored at –80 °C until analysis. Serum
IGF-I and IGFBP-3 concentrations were measured
using a 2-site coated tube immunoradiometric assay
(IRMA; Diagnostics Systems Laboratories, Webster,
TX, USA). Assays were performed according to the
manufacturer’s instructions. These assays are based
on noncompetitive IRMA in which the analyte to
be measured is sandwiched between 2 antibodies.
The IGF-I IRMA has a minimum detection limit of
2.06 ng/mL and intra- and interassay coefficients of
variation of 4.4% and 5.1%, and the IGFBP-3 IRMA
has a minimum detection limit of 0.5 ng/mL and
intra- and interassay coefficients of variation of 3.3%
and 3.9%, respectively.

Discussion
Gastric cancer is one of the most frequent neoplasms
and a leading cause of death worldwide. With
developments in molecular biology technology,
research on the mechanism of gastric carcinoma has
gone into deep molecular levels. Carcinogenesis is a
complicate process that includes many steps; many
gene abnormities may be involved in this process. There
was evidence that the effect of protooncologenes, the
inactivation of many antioncogenes, the regulation
of many growth factors and their receptors, the
accumulation of gene mutations, and imperfection of
the DNA rehabilitation system might play important
roles in the carcinogenesis and development of
gastric carcinoma. It is thought that the upregulation
of certain growth factors could play an important
role in the promotion and development of gastric
cancer (19,20).

Table 1. Patient characteristics regarding localization of gastric cancer.
Localization

Patient number

Corpus

11

Cardia

13

Antrum

6
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Table 2. Patient characteristics regarding metastatic site of gastric cancer.
Metastasis

Patient number

Liver + brain + lung

1

Peritoneum

7

Liver

18

Liver + lung

1

Spleen + lymph

1

Pancreas

1

Pancreas + surrenal gland

1

Most of the circulating IGF-I and IGFBP-3 are
synthesized in the liver, where expression of each is
increased by growth hormone. IGFBP-3 binds more
than 95% of the IGF in serum and influences cell
proliferation by modulating access of IGFs to the IGF
receptors. IGFBP-3 also apparently inhibits growth
and induces apoptosis through IGF- independent
mechanisms (21). There is considerable betweenperson variability in blood levels of IGF-I, IGF-II,
and IGFBP-3. Tissue IGF bioactivity is influenced by
circulating IGF levels and by local expression of IGFs,
IGFBPs, and IGFBP proteases. At the tissue level,
IGFBP-3 may regulate the interaction of IGF-I with its
receptor by inhibiting or augmenting the interaction
(2). Pollak et al. reported a strong positive association
between baseline plasma IGF-I levels and subsequent
risk of prostate cancer (22) or premenopausal breast
cancer (23). Results of some (24,25) but not all (26)
previous epidemiological studies have suggested
a possible direct relationship between circulating
IGF-I and colorectal cancer risk. The serum IGF-I
and IGFBP-3 levels were significantly elevated in
patients with esophageal cancer compared with the
control group and there was a positive correlation
between IGF-I and IGFBP-3 (27). Franciosi et al. (28)

showed that baseline IGF-I and IGFBP-3 levels were
significantly higher in patients with gastric cancer
than in healthy controls. This report showed that
tumor extension was not related to baseline IGF-I
levels. On postoperative day 14 in the patient group
a significant decrease in IGF-I levels was observed
versus baseline values. These data suggested that
surgical ablation of tumors may be able to reduce
IGF-I levels and this difference is present even in
the late postoperative period (day 50), showing that
the reduction in tumor load is closely related to
IGF-I decrease. IGFBP-3 levels after surgery were
not significantly different. In the present study, all
patients were in stage IV and had distant organ-tissue
metastases. The serum IGF-I and IGFBP-3 levels
were measured before the chemotherapy.
IGF-I might increase the risk of cancer through
its anti-apoptotic activity. In this case it prevents
the programmed death of cells that have been
transformed, thus interrupting an important process
that retards the development of cancer. Experiments
using animal and cell cultures have shown that the
anti-apoptotic activity of IGF-I is counterbalanced by
the activity of IGFBP-3, which may have a direct and
independent stimulatory action on apoptosis (29).

Table 3. Mean ± SD of IGF-I and IGFBP-3 in serum of patients with gastric cancer and controls.
IGF-I

IGF-I/IGFBP-3

Control group

228.3 ± 84.0

3284.4 ± 741.1

0.069 ± 0.016

Patient group

143.9 ± 60.1b

2476.3 ± 1180.4a

0.065 ± 0.028

a: P < 0.001, b: P < 0.0001 vs. control group
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In our study, the low serum IGF-I and IGFBP-3
levels detected in patients with gastric cancer could
be due to decreased synthesis and/or increased
catabolism of IGF-I.
Dae-Yeol et al. (30) reported that the serum
IGF-I level in gastric cancer was significantly
lower than in control subjects, and was further
decreased after surgery. They found that the
serum IGFBP-3 level was not significantly
different from those in control subjects, and a
decreased level of serum IGFBP-3 was found after
surgery.

In summary, we showed that serum IGF-I
and IGFBP-3 values in gastric cancer patients are
significantly decreased compared to the controls.
The difference between serum IGF-I/IGFBP-3 in
patients and controls was not significant. One may
suggest that these parameters are important in the
development and prognosis of gastric cancer and a
well-designed follow-up study is needed to confirm
these findings.
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